Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Isambert

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Therapie|April 2, 2003
[Thalidomide with or without dexamethasone for refractory multiple myeloma]M Boulin, F Blanchet, N Isambert, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2011
Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patientsKeyvan Rezai, S Urien, N Isambert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2009
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumoursN Isambert, M Campone, E Bourbouloux, et al.
ESMO Open|December 15, 2022
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumorsC Vicier, N Isambert, C Cropet, et al.
Case Reports in Oncology|August 26, 2010
Carcinomatous Meningitis from Unknown Primary CarcinomaL Favier, L Ladoire, B Guiu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2015
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phaseN Isambert, J-P Delord, J-C Soria, et al.
Anti-Cancer Drugs|November 15, 2001
Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinomaP Favoulet, J P Cercueil, P Faure, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 4, 2001
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot studyN Isambert, M Correia, J P Cercueil, et al.
British Journal of Cancer|July 14, 2012
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumoursG Freyer, N Isambert, B You, et al.
Targeted Oncology|December 25, 2012
Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implicationsA Italiano, E Saada, A Cioffi, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Therapie|April 2, 2003
[Thalidomide with or without dexamethasone for refractory multiple myeloma]M Boulin, F Blanchet, N Isambert, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2011
Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patientsKeyvan Rezai, S Urien, N Isambert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2009
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumoursN Isambert, M Campone, E Bourbouloux, et al.
ESMO Open|December 15, 2022
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumorsC Vicier, N Isambert, C Cropet, et al.
Case Reports in Oncology|August 26, 2010
Carcinomatous Meningitis from Unknown Primary CarcinomaL Favier, L Ladoire, B Guiu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2015
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phaseN Isambert, J-P Delord, J-C Soria, et al.
Anti-Cancer Drugs|November 15, 2001
Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinomaP Favoulet, J P Cercueil, P Faure, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 4, 2001
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot studyN Isambert, M Correia, J P Cercueil, et al.
British Journal of Cancer|July 14, 2012
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumoursG Freyer, N Isambert, B You, et al.
Targeted Oncology|December 25, 2012
Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implicationsA Italiano, E Saada, A Cioffi, et al.
Pageof 6